CoChat

Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs

Open access

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Abstract

We have identified a precursor that differentiates into granulocytes in vitro and in vivo yet belongs to the monocytic lineage. We have termed these cells monocyte-like precursors of granulocytes (MLPGs). Under steady state conditions, MLPGs were absent in the spleen and barely detectable in the bone marrow (BM). In contrast, these cells significantly expanded in tumor-bearing mice and differentiated to polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). Selective depletion of monocytic cells had no effect on the number of granulocytes in naive mice but decreased the population of PMN-MDSCs in tumor-bearing mice by 50%. The expansion of MLPGs was found to be controlled by the down-regulation of Rb1, but not IRF8, which is known to regulate the expansion of PMN-MDSCs from classic granulocyte precursors. In cancer patients, putative MLPGs were found within the population of CXCR1+CD15−CD14+HLA-DR−/lo monocytic cells. These findings describe a mechanism of abnormal myelopoiesis in cancer and suggest potential new approaches for selective targeting of MDSCs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20181952

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract
Graphical abstract CC BY-NC-SA · PubMed Central
Figure 1. Identification of monocytic precursors of granulocytes in TB mice. (A) Rb1 expression in CD11b+Ly6ChiLy6G− monocytic cells in BM of EL-4 TB Rb1-GFP reporter mice assessed by flow cytometry. Numbers in the plots indicate the percentage of gated cells. Typical example of three experiments is shown. (B) Rb1 expression in CD11b+Ly6ChiLy6G− monocytic cells in BM and spleens of TB and naive Rb1-GFP reporter mice. Mean and SD are shown of 13 TB and 13 tumor-free mice. P values were calculated by two-tailed Student’s t test. ****, P < 0.0001. (C) Rb1 expression in CD11b+Ly6ChiLy6G− monocytic cells in BM of naive Rb1-GFP reporter mice assessed by flow cytometry. Numbers in the plots indicate the percentage of gated cells. Typical example of three experiments is shown. (D) Phenotype of cells recovered after 3 d of culture with GM-CSF and TES of Rb1lo and Rb1hiCD11b+Ly6ChiLy6G− monocytic cells isolated from BM of EL-4 TB Rb1-GFP reporter mice. Numbers in the plots indicate the percentage of gated cells. Typical example of four experiments is shown. (E) Rb1 and CD117 expression in CD11b+Ly6ChiLy6G− monocytic cells from BM of EL-4 TB Rb1-GFP reporter mice assessed by flow cytometry. Numbers in the plots indicate the percentage of gated cells. Typical example of 13 experiments is shown. (F) Rb1 expression in CD117+ and CD117−CD11b+Ly6ChiLy6G− monocytic cells and CD11b+Ly6CintLy6G+ PMN-MDSCs in BM of EL-4 TB Rb1-GFP reporter mice. Mean and SD of three experiments are shown. *, P < 0.5; **, P < 0.01; ***, P < 0.001 by two-tailed Student’s t test. MFI, mean fluorescence intensity. (G) Antigen-specific proliferation of CD8+ T cells in the presence of Rb1lo and Rb1hiCD11b+Ly6ChiLy6G− monocytic cells sorted from BM of EL-4 TB Rb1-GFP reporter mice. Proliferation was measured in triplicate by 3H thymidine uptake. PMEL T cells were used as responder cells in this antigen-specific suppression assay. No st., no stimulation; Pept., stimulation of splenocytes with gp 100–derived peptide. Mean and SD of typical example of three experiments is shown. **, P < 0.01 by two-tailed Student’s t test. Three experiments with the same results were performed. (H) Phenotype of cells recovered after 3 d of culture with GM-CSF and TES or M-CSF of CD117+ and CD117−CD11b+Ly6ChiLy6G− monocytic cells sorted from BM of EL-4 TB mice. Numbers in the plots indicate the percentage of gated cells. Typical example of three experiments is shown. (I) Wright-Giemsa staining of cells differentiated with GM-CSF and TES from indicated precursors. Scale bar, 20 µm. Typical example of three experiments is shown. (J) In vivo differentiation of CD45.2+CD117+CD11b+Ly6ChiLy6G− monocytic cells transferred to sublethally irradiated EL-4 TB CD45.1+ recipient. Typical example of two experiments is shown. CPM, counts per minute; SSC, side scatter.
Figure 1. Identification of monocytic precursors of granulocytes in TB mice. (A) Rb1 expression in CD11b+Ly6ChiLy6G− monocytic cells in BM of EL-4 TB Rb1-GFP reporter mice assessed by flow cytometry. Numbers in the plots indicate the percentage of gated cells. Typical example of three experiments is shown. (B) Rb1 expression in CD11b+Ly6ChiLy6G− monocytic cells in BM and spleens of TB and naive Rb1-GFP reporter mice. Mean and SD are shown of 13 TB and 13 tumor-free mice. P values were calculated by two-tailed Student’s t test. ****, P < 0.0001. (C) Rb1 expression in CD11b+Ly6ChiLy6G− monocytic cells in BM of naive Rb1-GFP reporter mice assessed by flow cytometry. Numbers in the plots indicate the percentage of gated cells. Typical example of three experiments is shown. (D) Phenotype of cells recovered after 3 d of culture with GM-CSF and TES of Rb1lo and Rb1hiCD11b+Ly6ChiLy6G− monocytic cells isolated from BM of EL-4 TB Rb1-GFP reporter mice. Numbers in the plots indicate the percentage of gated cells. Typical example of four experiments is shown. (E) Rb1 and CD117 expression in CD11b+Ly6ChiLy6G− monocytic cells from BM of EL-4 TB Rb1-GFP reporter mice assessed by flow cytometry. Numbers in the plots indicate the percentage of gated cells. Typical example of 13 experiments is shown. (F) Rb1 expression in CD117+ and CD117−CD11b+Ly6ChiLy6G− monocytic cells and CD11b+Ly6CintLy6G+ PMN-MDSCs in BM of EL-4 TB Rb1-GFP reporter mice. Mean and SD of three experiments are shown. *, P < 0.5; **, P < 0.01; ***, P < 0.001 by two-tailed Student’s t test. MFI, mean fluorescence intensity. (G) Antigen-specific proliferation of CD8+ T cells in the presence of Rb1lo and Rb1hiCD11b+Ly6ChiLy6G− monocytic cells sorted from BM of EL-4 TB Rb1-GFP reporter mice. Proliferation was measured in triplicate by 3H thymidine uptake. PMEL T cells were used as responder cells in this antigen-specific suppression assay. No st., no stimulation; Pept., stimulation of splenocytes with gp 100–derived peptide. Mean and SD of typical example of three experiments is shown. **, P < 0.01 by two-tailed Student’s t test. Three experiments with the same results were performed. (H) Phenotype of cells recovered after 3 d of culture with GM-CSF and TES or M-CSF of CD117+ and CD117−CD11b+Ly6ChiLy6G− monocytic cells sorted from BM of EL-4 TB mice. Numbers in the plots indicate the percentage of gated cells. Typical example of three experiments is shown. (I) Wright-Giemsa staining of cells differentiated with GM-CSF and TES from indicated precursors. Scale bar, 20 µm. Typical example of three experiments is shown. (J) In vivo differentiation of CD45.2+CD117+CD11b+Ly6ChiLy6G− monocytic cells transferred to sublethally irradiated EL-4 TB CD45.1+ recipient. Typical example of two experiments is shown. CPM, counts per minute; SSC, side scatter.CC BY-NC-SA · PubMed Central
Figure 2. The monocytic nature of MLPGs. (A) CCR2 expression in CD117− and CD117+CD11b+Ly6ChiLy6G− M-MDSCs and MLPGs in BM of EL-4 TB mice assessed by flow cytometry. Numbers in the plots indicate the percentage of gated cells. Typical example of three experiments is shown. (B) May-Grünwald-Giemsa staining of CD117−CD11b+Ly6ChiLy6G− M-MDSCs, CD117+CD11b+Ly6ChiLy6G− MLPGs, CD117+CD11b+Ly6CintLy6G− GPs, and Lin−Sca-1−CD117+CD34+CD16/32hi GMPs sorted from BM of EL-4 TB mice. Scale bar, 20 µm. (C) CCR2 and SiglecF expression in Ly6Chi and Ly6CintCD11b+Ly6G− populations in BM of EL-4 TB mice assessed by flow cytometry. Numbers in the plots indicate the percentage of gated cells. Typical example of three experiments is shown. (D) Comparison of the transcriptomes of CD11b+Ly6ChiLy6G−CD117+ MLGP and CD11b+Ly6CintLy6G−CD117+ GPs from BM of EL-4 TB mice with transcriptomic profiles of different populations of hematopoietic cells and progenitors from the Immgen website. Cell types from the Immgen Consortium whose expression profiles correlated the most with MLPGs and GPs are shown. (E) tSNE clustering of granulocytes and monocytes with MLPGs and GPs. *, intermediate; 6C, Ly6C; Arth, arthritic; bl, blood; GN, granulocytes; II, MHCII; Mo, monocytes; PC, peritoneal cavity; SSC, side scatter; SF/SynF, synovial fluid; Thio, thioglycolate; UrAc, uric acid.
Figure 2. The monocytic nature of MLPGs. (A) CCR2 expression in CD117− and CD117+CD11b+Ly6ChiLy6G− M-MDSCs and MLPGs in BM of EL-4 TB mice assessed by flow cytometry. Numbers in the plots indicate the percentage of gated cells. Typical example of three experiments is shown. (B) May-Grünwald-Giemsa staining of CD117−CD11b+Ly6ChiLy6G− M-MDSCs, CD117+CD11b+Ly6ChiLy6G− MLPGs, CD117+CD11b+Ly6CintLy6G− GPs, and Lin−Sca-1−CD117+CD34+CD16/32hi GMPs sorted from BM of EL-4 TB mice. Scale bar, 20 µm. (C) CCR2 and SiglecF expression in Ly6Chi and Ly6CintCD11b+Ly6G− populations in BM of EL-4 TB mice assessed by flow cytometry. Numbers in the plots indicate the percentage of gated cells. Typical example of three experiments is shown. (D) Comparison of the transcriptomes of CD11b+Ly6ChiLy6G−CD117+ MLGP and CD11b+Ly6CintLy6G−CD117+ GPs from BM of EL-4 TB mice with transcriptomic profiles of different populations of hematopoietic cells and progenitors from the Immgen website. Cell types from the Immgen Consortium whose expression profiles correlated the most with MLPGs and GPs are shown. (E) tSNE clustering of granulocytes and monocytes with MLPGs and GPs. *, intermediate; 6C, Ly6C; Arth, arthritic; bl, blood; GN, granulocytes; II, MHCII; Mo, monocytes; PC, peritoneal cavity; SSC, side scatter; SF/SynF, synovial fluid; Thio, thioglycolate; UrAc, uric acid.CC BY-NC-SA · PubMed Central
Figure 3. The nature of MLPGs. (A) CX3CR1 expression in CD117−CD11b+Ly6ChiLy6G− M-MDSCs, CD117+CD11b+Ly6ChiLy6G− MLPGs, CD117+CD11b+Ly6CintLy6G− GPs, and CD11b+Ly6CintLy6G+ PMN-MDSCs in BM of CX3CR1-GFP+ EL-4 TB mice. As a positive control, CD117−CD11b+Ly6CintLy6G− monocytes were used. Top: Typical example of staining. Bottom: Mean and SD from five mice per group are shown. ****, P < 0.0001 by two-tailed Student’s t test. MFI, mean fluorescence intensity. (B) Pattern of CX3CR1 expression in MLPGs in EL-4 TB mice. CX3CR1 expression in CD11b+Ly6ChiLy6G− monocytic cells in BM of EL-4 TB CX3CR1 reporter mice assessed by flow cytometry. Numbers in the plots indicate the percentage of gated cells. Expression of CX3CR1 is shown for individual mice (n = 5). (C and D) Differentiation of CD45.2+ GMPs isolated from the BM of EL-4 TB mice after adoptive transfer to sublethally irradiated CD45.1+ EL-4 TB recipient mice. CD45.2+ donor cells were evaluated by flow cytometry in spleens of CD45.1+ recipient mice after 24 h. (C) Phenotype of cells before transfer. (D) Phenotype of cells differentiated from the donor’s GMPs 24 h after transfer. Two experiments with the same results were performed. SSC, side scatter.
Figure 3. The nature of MLPGs. (A) CX3CR1 expression in CD117−CD11b+Ly6ChiLy6G− M-MDSCs, CD117+CD11b+Ly6ChiLy6G− MLPGs, CD117+CD11b+Ly6CintLy6G− GPs, and CD11b+Ly6CintLy6G+ PMN-MDSCs in BM of CX3CR1-GFP+ EL-4 TB mice. As a positive control, CD117−CD11b+Ly6CintLy6G− monocytes were used. Top: Typical example of staining. Bottom: Mean and SD from five mice per group are shown. ****, P < 0.0001 by two-tailed Student’s t test. MFI, mean fluorescence intensity. (B) Pattern of CX3CR1 expression in MLPGs in EL-4 TB mice. CX3CR1 expression in CD11b+Ly6ChiLy6G− monocytic cells in BM of EL-4 TB CX3CR1 reporter mice assessed by flow cytometry. Numbers in the plots indicate the percentage of gated cells. Expression of CX3CR1 is shown for individual mice (n = 5). (C and D) Differentiation of CD45.2+ GMPs isolated from the BM of EL-4 TB mice after adoptive transfer to sublethally irradiated CD45.1+ EL-4 TB recipient mice. CD45.2+ donor cells were evaluated by flow cytometry in spleens of CD45.1+ recipient mice after 24 h. (C) Phenotype of cells before transfer. (D) Phenotype of cells differentiated from the donor’s GMPs 24 h after transfer. Two experiments with the same results were performed. SSC, side scatter.CC BY-NC-SA · PubMed Central
Figure 4. Differentiation of MLPGs. (A) Example of gating strategy and proportion of CD115+ cells among CD11b+Ly6ChiLy6G−CD117+ MLPGs from BM of EL4-TB mice. Three mice were evaluated. The results of individual experiments, mean and SD, are shown. (B) CD115− and CD115+ MLPGs were sorted from the BM of EL-4 TB mice and cultured for 3 d with GM-CSF with or without TES (20% vol/vol). The frequencies of CD115+Ly6G− monocytic cells and of CD115−Ly6G+ granulocytic cells obtained upon differentiation of both subsets of MLPGs are shown. The results of individual experiments (n = 5), mean and SD, are shown. **, P < 0.01; ****, P < 0.0001 by two-tailed Student’s t test. (C) CX3CR1 expression was measured using naive reporter mice in the indicated cell populations. The results of individual experiments (n = 3), mean and SD, are shown. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001 by two-tailed Student’s t test. MFI, mean fluorescence intensity. (D) Example of phenotype of cells recovered after 3 d of culture with GM-CSF of CD11b+Ly6ChiLy6G−CD117− monocytes and CD11b+Ly6ChiLy6G−CD117+ MLPGs sorted from BM of naive mice. Numbers in the plots indicate the percentage of gated cells. (E) Numbers of cells generated from naive or EL-4 BM MLPGs after 3-d culture in complete RPMI with GM-CSF. Results of five experiments are shown. *, P < 0.05. (F) Antigen-specific proliferation of CD8+ T cells in the presence of Ly6G+ cells isolated after cultures of naive or EL-4 TB BM MLPGs. Cultures were done with GM-CSF and additional TES for EL-4 BM MLPGs. Proliferation was measured in triplicate by 3H thymidine uptake. PMEL T cells were used as responder cells in this antigen-specific suppression assay. Mean and SD are shown. Two experiments with similar results were performed. *, P < 0.05; ***, P < 0.001 by two-tailed Student’s t test. No stim, no stimulation; cpm, counts per minute; SSC, side scatter.
Figure 4. Differentiation of MLPGs. (A) Example of gating strategy and proportion of CD115+ cells among CD11b+Ly6ChiLy6G−CD117+ MLPGs from BM of EL4-TB mice. Three mice were evaluated. The results of individual experiments, mean and SD, are shown. (B) CD115− and CD115+ MLPGs were sorted from the BM of EL-4 TB mice and cultured for 3 d with GM-CSF with or without TES (20% vol/vol). The frequencies of CD115+Ly6G− monocytic cells and of CD115−Ly6G+ granulocytic cells obtained upon differentiation of both subsets of MLPGs are shown. The results of individual experiments (n = 5), mean and SD, are shown. **, P < 0.01; ****, P < 0.0001 by two-tailed Student’s t test. (C) CX3CR1 expression was measured using naive reporter mice in the indicated cell populations. The results of individual experiments (n = 3), mean and SD, are shown. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001 by two-tailed Student’s t test. MFI, mean fluorescence intensity. (D) Example of phenotype of cells recovered after 3 d of culture with GM-CSF of CD11b+Ly6ChiLy6G−CD117− monocytes and CD11b+Ly6ChiLy6G−CD117+ MLPGs sorted from BM of naive mice. Numbers in the plots indicate the percentage of gated cells. (E) Numbers of cells generated from naive or EL-4 BM MLPGs after 3-d culture in complete RPMI with GM-CSF. Results of five experiments are shown. *, P < 0.05. (F) Antigen-specific proliferation of CD8+ T cells in the presence of Ly6G+ cells isolated after cultures of naive or EL-4 TB BM MLPGs. Cultures were done with GM-CSF and additional TES for EL-4 BM MLPGs. Proliferation was measured in triplicate by 3H thymidine uptake. PMEL T cells were used as responder cells in this antigen-specific suppression assay. Mean and SD are shown. Two experiments with similar results were performed. *, P < 0.05; ***, P < 0.001 by two-tailed Student’s t test. No stim, no stimulation; cpm, counts per minute; SSC, side scatter.CC BY-NC-SA · PubMed Central
Figure 5. Population of MLPGs in TB mice. (A) Total cell number of MLPGs in BM and PMNs/PMN-MDSCs in spleens of naive or TB mice 3–4 wk after subcutaneous inoculation of the indicated tumor cells to C57BL/6 mice. Results of individual mice are shown (5–12 mice per group). (B) Total cell number of MLPGs in BM and PMNs/PMN-MDSCs in spleens of naive or CT26 TB mice BALB/c mice 3–4 wk after subcutaneous inoculation of the tumor cells. Results of individual mice are shown (3–5 mice per group). (C) Total number of MLPGs in spleens of B16F10 and CT26 TB mice 3–4 wk after subcutaneous inoculation of the tumor cells. Results of individual mice are shown (6–9 mice per group). (D) Total cell number of MLPGs in BM and spleens, and PMNs/PMN-MDSCs in spleens of control (PC) or KPC mice. Results of individual mice are shown (three mice per group). (E) Total cell number of MLPGs in BM and spleens, and PMNs/PMN-MDSCs in spleens of control or TRAMP mice. Results of individual mice are shown (three mice per group). (F) Total cell number of MLPGs in BM and spleens, and PMNs/PMN-MDSCs in spleens of control or RET melanoma mice. 3–11 mice were used in each experiment, and the number of mice evaluated is shown in each panel. Values of mean and SD are shown. *, P ≤ 0.05; **, P ≤ 0.01; ***, P < 0.001; ****, P ≤ 0.0001 by two-tailed Student’s t test. (G) Correlation between total cell numbers of MLPGs in BM and total cell numbers of PMN-MDSCs in spleens in all C57BL/6 TB mice described above. Spearman coefficient was used to calculate correlation.
Figure 5. Population of MLPGs in TB mice. (A) Total cell number of MLPGs in BM and PMNs/PMN-MDSCs in spleens of naive or TB mice 3–4 wk after subcutaneous inoculation of the indicated tumor cells to C57BL/6 mice. Results of individual mice are shown (5–12 mice per group). (B) Total cell number of MLPGs in BM and PMNs/PMN-MDSCs in spleens of naive or CT26 TB mice BALB/c mice 3–4 wk after subcutaneous inoculation of the tumor cells. Results of individual mice are shown (3–5 mice per group). (C) Total number of MLPGs in spleens of B16F10 and CT26 TB mice 3–4 wk after subcutaneous inoculation of the tumor cells. Results of individual mice are shown (6–9 mice per group). (D) Total cell number of MLPGs in BM and spleens, and PMNs/PMN-MDSCs in spleens of control (PC) or KPC mice. Results of individual mice are shown (three mice per group). (E) Total cell number of MLPGs in BM and spleens, and PMNs/PMN-MDSCs in spleens of control or TRAMP mice. Results of individual mice are shown (three mice per group). (F) Total cell number of MLPGs in BM and spleens, and PMNs/PMN-MDSCs in spleens of control or RET melanoma mice. 3–11 mice were used in each experiment, and the number of mice evaluated is shown in each panel. Values of mean and SD are shown. *, P ≤ 0.05; **, P ≤ 0.01; ***, P < 0.001; ****, P ≤ 0.0001 by two-tailed Student’s t test. (G) Correlation between total cell numbers of MLPGs in BM and total cell numbers of PMN-MDSCs in spleens in all C57BL/6 TB mice described above. Spearman coefficient was used to calculate correlation.CC BY-NC-SA · PubMed Central
Figure 6. Contribution of MLPGs to PMN-MDSC accumulation in TB mice. (A) Schema of depletion of monocytic cells in CX3CR1CreER+ ROSA-DTRfl/fl EL-4 TB mice. (B) Example of flow cytometry analysis performed in blood samples from naive or EL-4 TB CX3CR1CreER+ ROSA-DTRfl/fl mice treated with Tm with or without subsequent DT injection. Note the efficient depletion of CD11b+CX3CR1+Ly6Clo/− patrolling monocytes. (C and D) Results of individual mice are shown in the figures (6–10 mice per group). Percentage (C) and total cell numbers (D) of PMNs/PMN-MDSCs in spleens of naive, EL-4, or LL-2 TB CX3CR1CreER− and CX3CR1CreER+ ROSA-DTRfl/fl mice. (E and F) Results of individual mice are shown in the figures (five to six mice per group). Percentage (E) and total cell numbers (F) of PMNs/PMN-MDSCs in BM of naive, EL-4, or LL-2 TB CX3CR1CreER− and CX3CR1CreER+ ROSA-DTRfl/fl mice. Result from each tested mouse as well as mean and SD are shown. Individual P values (*, P < 0.05; **, P < 0.01; ***, P < 0.001) by two-tailed Student’s t test are shown. (G) M-MDSC population in CX3CR1CreER− and CX3CR1Cre-ER+ Rosa-DTRfl/fl LL2 TB mice. Total cell numbers of M-MDSCs in spleens and BM are shown. Result from each tested mouse (n = 7) as well as mean and SD are shown. Individual P values (*, P < 0.05) by two-tailed Student’s t test are shown. (H) Tumor size in CX3CR1CreER− and CX3CR1Cre-ER+ Rosa-DTRfl/fl EL-4 TB mice at day 16 at the time of sacrifice. Result from each tested mouse (n = 8–10) as well as mean and SD are shown. Individual P values (*, P < 0.05) by two-tailed Student’s t test are shown. (I) EG7 tumors were established s.c. in CX3CR1CreER− and CX3CR1Cre-ER+ Rosa-DTRfl/fl mice. 10 d after tumor inoculation, when tumor became palpable, mice were treated with Tm (4 mg per day) for 8 d and DT injections (1 µg in 200 µl of PBS) on days 6 and 8. 1 d after that, spleen CD8+ T cells were isolated and stimulated with the OVA-derived SIINFEKL peptide, and their IFN-γ production was measured in an ELISpot assay (n = 3). P values were calculated by Student’s t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P ≤ 0.0001. SSC, side scatter.
Figure 6. Contribution of MLPGs to PMN-MDSC accumulation in TB mice. (A) Schema of depletion of monocytic cells in CX3CR1CreER+ ROSA-DTRfl/fl EL-4 TB mice. (B) Example of flow cytometry analysis performed in blood samples from naive or EL-4 TB CX3CR1CreER+ ROSA-DTRfl/fl mice treated with Tm with or without subsequent DT injection. Note the efficient depletion of CD11b+CX3CR1+Ly6Clo/− patrolling monocytes. (C and D) Results of individual mice are shown in the figures (6–10 mice per group). Percentage (C) and total cell numbers (D) of PMNs/PMN-MDSCs in spleens of naive, EL-4, or LL-2 TB CX3CR1CreER− and CX3CR1CreER+ ROSA-DTRfl/fl mice. (E and F) Results of individual mice are shown in the figures (five to six mice per group). Percentage (E) and total cell numbers (F) of PMNs/PMN-MDSCs in BM of naive, EL-4, or LL-2 TB CX3CR1CreER− and CX3CR1CreER+ ROSA-DTRfl/fl mice. Result from each tested mouse as well as mean and SD are shown. Individual P values (*, P < 0.05; **, P < 0.01; ***, P < 0.001) by two-tailed Student’s t test are shown. (G) M-MDSC population in CX3CR1CreER− and CX3CR1Cre-ER+ Rosa-DTRfl/fl LL2 TB mice. Total cell numbers of M-MDSCs in spleens and BM are shown. Result from each tested mouse (n = 7) as well as mean and SD are shown. Individual P values (*, P < 0.05) by two-tailed Student’s t test are shown. (H) Tumor size in CX3CR1CreER− and CX3CR1Cre-ER+ Rosa-DTRfl/fl EL-4 TB mice at day 16 at the time of sacrifice. Result from each tested mouse (n = 8–10) as well as mean and SD are shown. Individual P values (*, P < 0.05) by two-tailed Student’s t test are shown. (I) EG7 tumors were established s.c. in CX3CR1CreER− and CX3CR1Cre-ER+ Rosa-DTRfl/fl mice. 10 d after tumor inoculation, when tumor became palpable, mice were treated with Tm (4 mg per day) for 8 d and DT injections (1 µg in 200 µl of PBS) on days 6 and 8. 1 d after that, spleen CD8+ T cells were isolated and stimulated with the OVA-derived SIINFEKL peptide, and their IFN-γ production was measured in an ELISpot assay (n = 3). P values were calculated by Student’s t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P ≤ 0.0001. SSC, side scatter.CC BY-NC-SA · PubMed Central
Figure 7. Rb1 regulates MLPG expansion while IRF8 controls GP accumulation. Results of individual mice are shown (5–11 mice per group). (A) Total cell numbers of MLPGs in BM (left) and spleens (right) in WT or Rb1 KO naive mice. (B) Total cell numbers of MLPGs in BM (left) and spleens (right) in control mice (p107+/−) or Rb TKO naive mice. (C) Expression of irf8 in MLPGs. Expression of irf8 (normalized to β-actin) in BM MLPGs from naive mice. Monocytes and neutrophils are presented as controls. Gene expression was evaluated by quantitative RT-PCR in three independent experiments, each performed in triplicate. Mean and SD of each measurement in triplicate is shown. (D) Rb1 expression in CD117+CD11b+Ly6ChiLy6G− MLPGs and CD117+CD11b+Ly6CintLy6G− GPs in BM of EL-4 and LL2 TB Rb1-GFP reporter mice. Individual results and mean and SD are shown. P values were calculated by two-sided Student’s t test. MFI, mean fluorescence intensity. (E) Total cell numbers of neutrophils in BM of WT mice and Rb1 KO or IRF8 KO mice. (F) Total cell numbers of MLPGs and GPs in BM of WT mice and Rb1 KO or IRF8 KO mice. Mean and SEM are shown. In experiments with Rb1 KO mice, n = 6, and with IRF8 KO mice, n = 4. P values were calculated by two-tailed Student’s t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. (G) Growth of subcutaneous EL-4 tumor injected into WT and Rb1 KO mice. Results in individual mice (n = 5) are shown. (H) Total cell numbers of BM and spleen MLPGs and GPs in WT and Rb1 KO EL-4 TB mice. Values in individual mice (n = 5) and mean and SD are shown. P values were calculated by two-tailed Student’s t test. **, P < 0.01; ****, P < 0.0001. (I) Growth of subcutaneous MC38 tumors injected into WT and Rb1 KO mice. Results in individual mice (n = 4) are shown. P value was calculated by two-way ANOVA.
Figure 7. Rb1 regulates MLPG expansion while IRF8 controls GP accumulation. Results of individual mice are shown (5–11 mice per group). (A) Total cell numbers of MLPGs in BM (left) and spleens (right) in WT or Rb1 KO naive mice. (B) Total cell numbers of MLPGs in BM (left) and spleens (right) in control mice (p107+/−) or Rb TKO naive mice. (C) Expression of irf8 in MLPGs. Expression of irf8 (normalized to β-actin) in BM MLPGs from naive mice. Monocytes and neutrophils are presented as controls. Gene expression was evaluated by quantitative RT-PCR in three independent experiments, each performed in triplicate. Mean and SD of each measurement in triplicate is shown. (D) Rb1 expression in CD117+CD11b+Ly6ChiLy6G− MLPGs and CD117+CD11b+Ly6CintLy6G− GPs in BM of EL-4 and LL2 TB Rb1-GFP reporter mice. Individual results and mean and SD are shown. P values were calculated by two-sided Student’s t test. MFI, mean fluorescence intensity. (E) Total cell numbers of neutrophils in BM of WT mice and Rb1 KO or IRF8 KO mice. (F) Total cell numbers of MLPGs and GPs in BM of WT mice and Rb1 KO or IRF8 KO mice. Mean and SEM are shown. In experiments with Rb1 KO mice, n = 6, and with IRF8 KO mice, n = 4. P values were calculated by two-tailed Student’s t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. (G) Growth of subcutaneous EL-4 tumor injected into WT and Rb1 KO mice. Results in individual mice (n = 5) are shown. (H) Total cell numbers of BM and spleen MLPGs and GPs in WT and Rb1 KO EL-4 TB mice. Values in individual mice (n = 5) and mean and SD are shown. P values were calculated by two-tailed Student’s t test. **, P < 0.01; ****, P < 0.0001. (I) Growth of subcutaneous MC38 tumors injected into WT and Rb1 KO mice. Results in individual mice (n = 4) are shown. P value was calculated by two-way ANOVA.CC BY-NC-SA · PubMed Central
Figure 8. Mechanism of MLPG expansion in TB mice. (A) Proliferation of BM MLPGs from naive and EL-4 TB mice in vitro assessed by BrdU uptake (left) and 3H thymidine incorporation (right) after 20 h of culture in complete RPMI without cytokines (n = 4). (B) Frequency of Annexin V+ BM MLPGs from naive and EL-4 TB mice after 20 h of culture in complete RPMI without cytokines (n = 7). (C) Frequency of Annexin V+ BM MLPGs from naive and EL-4 TB mice cultured in the presence of 5% vol/vol EL-4 TES for 20 h in complete RPMI without cytokines (n = 4). (D) Proliferation of BM WT and Rb1 KO MLPGs in vitro, assessed by BrdU uptake after 20 h of culture in complete RPMI without cytokines (n = 4). (E) Proliferation of BM WT and Rb1 KO MLPGs in vivo, assessed by BrdU uptake. Frequency of BrdU+ cells was evaluated 4 h after i.p. injection of BrdU (n = 3). (F) Frequency of Annexin V+ BM WT and Rb1 KO MLPGs 20 h after culture in complete RPMI without cytokines (n = 6). (G) Numbers of cells generated from EL-4 BM CD11b+Ly6ChiLy6G−CD117− M-MDSCs and CD11b+Ly6ChiLy6G−CD117+ MLPGs after 3-d culture in RPMI (supplemented or not with FBS) with or without addition of the indicated cytokines. Dashed line, starting number of cells (n = 6); Lip, lipids. (H) Frequency of live cells from the experiments described in G (n = 6). (I) Frequency of Ly6G+ cells generated from the MLPG cultures described in G (n = 6). (J) Numbers of cells generated from EL-4 BM MLPGs cultured for 3 d in serum-free media (SFM) with or without the indicated cytokines. Complete RPMI was used as a positive control (n = 4). P values were calculated by two-tailed Student’s t test. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. Mean and SD are shown.
Figure 8. Mechanism of MLPG expansion in TB mice. (A) Proliferation of BM MLPGs from naive and EL-4 TB mice in vitro assessed by BrdU uptake (left) and 3H thymidine incorporation (right) after 20 h of culture in complete RPMI without cytokines (n = 4). (B) Frequency of Annexin V+ BM MLPGs from naive and EL-4 TB mice after 20 h of culture in complete RPMI without cytokines (n = 7). (C) Frequency of Annexin V+ BM MLPGs from naive and EL-4 TB mice cultured in the presence of 5% vol/vol EL-4 TES for 20 h in complete RPMI without cytokines (n = 4). (D) Proliferation of BM WT and Rb1 KO MLPGs in vitro, assessed by BrdU uptake after 20 h of culture in complete RPMI without cytokines (n = 4). (E) Proliferation of BM WT and Rb1 KO MLPGs in vivo, assessed by BrdU uptake. Frequency of BrdU+ cells was evaluated 4 h after i.p. injection of BrdU (n = 3). (F) Frequency of Annexin V+ BM WT and Rb1 KO MLPGs 20 h after culture in complete RPMI without cytokines (n = 6). (G) Numbers of cells generated from EL-4 BM CD11b+Ly6ChiLy6G−CD117− M-MDSCs and CD11b+Ly6ChiLy6G−CD117+ MLPGs after 3-d culture in RPMI (supplemented or not with FBS) with or without addition of the indicated cytokines. Dashed line, starting number of cells (n = 6); Lip, lipids. (H) Frequency of live cells from the experiments described in G (n = 6). (I) Frequency of Ly6G+ cells generated from the MLPG cultures described in G (n = 6). (J) Numbers of cells generated from EL-4 BM MLPGs cultured for 3 d in serum-free media (SFM) with or without the indicated cytokines. Complete RPMI was used as a positive control (n = 4). P values were calculated by two-tailed Student’s t test. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. Mean and SD are shown.CC BY-NC-SA · PubMed Central
Figure 9. MLPGs in humans. (A) Analysis of 619 genes significantly differentially expressed (FDR <5%) in M-MDSCs compared with monocytes from lung cancer patients. Expression heatmap for a gene subset specific to neutrophils and monocytes/macrophages and top significant genes. Mono, monocyte. (B) Functions significantly enriched among significant genes as identified by Ingenuity Pathway Analysis. (C) Proportion of CXCR1+ cells among healthy donor (HD) and prostate cancer patient CD14+CD15−HLA-DRhi monocytes (Mon) and among CD14+CD15−HLA-DRlo/− M-MDSCs from the same patients. Results from individual patients are shown (n = 8). Mean and SD are shown. ****, P < 0.0001 by two-sided Student’s t test. Mon, monocyte. (D) CXCR1+CD14+CD15−HLA-DRlo/− and CXCR1− CD14+CD15−HLA-DRlo/− M-MDSCs were sorted from the peripheral blood of cancer patients and used in a three-way allogeneic mixed leukocyte reaction using dendritic cells (DC) and T cells from unrelated donors. T cell proliferation was measured in triplicate, and mean and SD are shown. P values were calculated by Student’s t test. *, P < 0.05; **, P < 0.01; ***, P < 0.0001. (E) Differentiation of neutrophils from the indicated monocytic populations after 4-d culture on OP-9 feeder cells with G-CSF and GM-CSF. A typical example is shown. May-Grünwald-Giemsa staining on the left; staining for naphthol-AS-chloroacetate esterase (napththol-AS-chlor.acet. Est) activity on the right. Four experiments with the same results were performed. Scale bar, 20 µm. (F) Frequency of neutrophils differentiated from monocytes and M-MDSCs isolated from cancer patients after 4 d culture on OP-9 feeder cells with G-CSF and GM-CSF. Values for each patient are shown (n = 4). In all experiments, mean and SD values are shown. P values were calculated by Student’s t test. *, P < 0.05; **, P < 0.01. cpm, counts per minute.
Figure 9. MLPGs in humans. (A) Analysis of 619 genes significantly differentially expressed (FDR <5%) in M-MDSCs compared with monocytes from lung cancer patients. Expression heatmap for a gene subset specific to neutrophils and monocytes/macrophages and top significant genes. Mono, monocyte. (B) Functions significantly enriched among significant genes as identified by Ingenuity Pathway Analysis. (C) Proportion of CXCR1+ cells among healthy donor (HD) and prostate cancer patient CD14+CD15−HLA-DRhi monocytes (Mon) and among CD14+CD15−HLA-DRlo/− M-MDSCs from the same patients. Results from individual patients are shown (n = 8). Mean and SD are shown. ****, P < 0.0001 by two-sided Student’s t test. Mon, monocyte. (D) CXCR1+CD14+CD15−HLA-DRlo/− and CXCR1− CD14+CD15−HLA-DRlo/− M-MDSCs were sorted from the peripheral blood of cancer patients and used in a three-way allogeneic mixed leukocyte reaction using dendritic cells (DC) and T cells from unrelated donors. T cell proliferation was measured in triplicate, and mean and SD are shown. P values were calculated by Student’s t test. *, P < 0.05; **, P < 0.01; ***, P < 0.0001. (E) Differentiation of neutrophils from the indicated monocytic populations after 4-d culture on OP-9 feeder cells with G-CSF and GM-CSF. A typical example is shown. May-Grünwald-Giemsa staining on the left; staining for naphthol-AS-chloroacetate esterase (napththol-AS-chlor.acet. Est) activity on the right. Four experiments with the same results were performed. Scale bar, 20 µm. (F) Frequency of neutrophils differentiated from monocytes and M-MDSCs isolated from cancer patients after 4 d culture on OP-9 feeder cells with G-CSF and GM-CSF. Values for each patient are shown (n = 4). In all experiments, mean and SD values are shown. P values were calculated by Student’s t test. *, P < 0.05; **, P < 0.01. cpm, counts per minute.CC BY-NC-SA · PubMed Central
Figure 10. Schema of neutrophil differentiation in cancer. In the steady state, neutrophil differentiation is the end point of the MPP–CMP–GMP–GP pathway. This pathway is negatively regulated by the IRF8 transcription factor. In steady state, the MLPG contribution to the neutrophil and monocyte pool is minimal. In cancer, down-regulation of IRF8 and Rb1 leads to expansion of both PMN-MDSC progenitors: GPs and their monocytic counterparts MLPGs. MLPGs, in some models, may contribute to 50% of the PMN-MDSC pool. CMLP, common myelolymphoid progenitor; HSC, hematopoietic stem cell; Mon, monocyte; MPP, multipotent progenitor.
Figure 10. Schema of neutrophil differentiation in cancer. In the steady state, neutrophil differentiation is the end point of the MPP–CMP–GMP–GP pathway. This pathway is negatively regulated by the IRF8 transcription factor. In steady state, the MLPG contribution to the neutrophil and monocyte pool is minimal. In cancer, down-regulation of IRF8 and Rb1 leads to expansion of both PMN-MDSC progenitors: GPs and their monocytic counterparts MLPGs. MLPGs, in some models, may contribute to 50% of the PMN-MDSC pool. CMLP, common myelolymphoid progenitor; HSC, hematopoietic stem cell; Mon, monocyte; MPP, multipotent progenitor.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 118

Metadata

Authors
Mastio, J., Condamine, T., Dominguez, G., Kossenkov, A. V., Donthireddy, L., Veglia, F., Lin, C., Wang, F., Fu, S., Zhou, J., Viatour, P., Lavilla-Alonso, S., Polo, A. T., Tcyganov, E. N., Mulligan, C., Nam, B., Bennett, J., Masters, G., Guarino, M., Kumar, A., Nefedova, Y., Vonderheide, R. H., Languino, L. R., Abrams, S. I., & Gabrilovich, D. I.
Affiliations
  • The Wistar Institute (US)
  • Sun Yat-sen University (CN)
  • University of Pennsylvania (US)
  • Asociación Demográfica Costarricense (CR)
  • Christiana Care Health System (US)
  • Thomas Jefferson University (US)
  • Roswell Park Comprehensive Cancer Center (US)
Corresponding author
Gabrilovich, Dmitry I.
Venue
Journal of Experimental Medicine
Published
2019-06-25
Volume
216
Issue
9
Pages
2150-2169
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2954317599
Cited by
115
References
52
Citations by year
2026: 5 · 2025: 17 · 2024: 12 · 2023: 22 · 2022: 22 · 2021: 23 · 2020: 10 · 2019: 4
FWCI
5.88
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • The Medicine Forum (submittedVersion, cc-by-nc-sa)
Funders
  • National Institutes of Health (CA084488, CA140043)
  • Wistar Institute Animal and Bioinformatics (P30 CA010815)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Keywords
polymorphonuclear myeloid-derived suppressor cells, RB1, IRF8, monocytic lineage, granulocytic differentiation, MDSC depletion, tumor immunosuppression
MeSH terms
Myeloid-Derived Suppressor Cells, Adult, Aged, Animals, Cell Differentiation, Female, Humans, Male, Mice, Inbred C57BL, Middle Aged, Monocytes, Neoplasms, Neutrophils, Mice, Retinoblastoma Binding Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs. https://app.cochat.ai/papers/10.1084/jem.20181952
The paper
Mastio, J., Condamine, T., Dominguez, G., Kossenkov, A. V., Donthireddy, L., Veglia, F., Lin, C., Wang, F., Fu, S., Zhou, J., Viatour, P., Lavilla-Alonso, S., Polo, A. T., Tcyganov, E. N., Mulligan, C., Nam, B., Bennett, J., Masters, G., Guarino, M., . . . Gabrilovich, D. I. (2019). Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20181952

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.